Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

[1]  Masahiro Yamamura,et al.  Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. , 2004, Arthritis and rheumatism.

[2]  J. Jośko,et al.  Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Wuyin Li.  Angiogenesis in rheumatoid arthritis , 2004 .

[4]  Y. Okada,et al.  Hypoxia-Inducible Factor Regulates Survival of Antigen Receptor-Driven T Cells 1 , 2003, The Journal of Immunology.

[5]  Ae-June Wang,et al.  A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  E. Esplugues,et al.  CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. , 2003, The Journal of clinical investigation.

[7]  Takeshi Inoue,et al.  Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. , 2003, Biochemical pharmacology.

[8]  E. Maltezos,et al.  Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis , 2003, Arthritis research & therapy.

[9]  H. Inoue,et al.  Effect of NOS2 gene deficiency on the development of autoantibody mediated arthritis and subsequent articular cartilage degeneration. , 2003, The Journal of rheumatology.

[10]  G. Haines,et al.  IL-6 and Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts1 , 2003, The Journal of Immunology.

[11]  Kyu-Won Kim,et al.  Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. , 2003, Biochemical and biophysical research communications.

[12]  N. Miyasaka,et al.  Treatment of Arthritis Exerts Anti-Inflammatory Effects in the Gene Transfer of a Cell Cycle Modulator , 2003 .

[13]  P. Lipsky,et al.  Targeted Therapies in Rheumatology , 2002 .

[14]  C. Hitchon,et al.  Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. , 2002, Arthritis and rheumatism.

[15]  E. Paleolog.  Angiogenesis in rheumatoid arthritis , 2002, Arthritis research.

[16]  H. Kwon,et al.  Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis , 2002, International journal of cancer.

[17]  D. Walsh,et al.  Angiogenesis: a therapeutic target in arthritis. , 2001, Current opinion in investigational drugs.

[18]  Eun-Joung Moon,et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.

[19]  P G Pelicci,et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.

[20]  A. Pardee,et al.  Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment , 2000, Molecular medicine.

[21]  J. Caro,et al.  Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. , 2000, The Biochemical journal.

[22]  W. Jelkmann,et al.  Interleukin-1β and Tumor Necrosis Factor- Stimulate DNA Binding of Hypoxia-Inducible Factor-1 , 1999 .

[23]  T. Naoe,et al.  Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy , 1999, Leukemia.

[24]  M. Grever,et al.  Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. , 1999, Blood.

[25]  W. Jelkmann,et al.  Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. , 1999, Blood.

[26]  G. Firestein,et al.  Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[27]  C. Allis,et al.  Roles of histone acetyltransferases and deacetylases in gene regulation , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[28]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[29]  M. Yoshida,et al.  FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. , 1998, Experimental cell research.

[30]  S. Schreiber,et al.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Schreiber,et al.  Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.

[32]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[33]  P. Baeuerle,et al.  Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. , 1997, Methods.

[34]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[35]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[36]  A. Kang,et al.  Induction of arthritis with monoclonal antibodies to collagen. , 1992, Journal of immunology.

[37]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[38]  I. Hemo,et al.  In vivo angiogenic activity of interleukins. , 1990, Archives of ophthalmology.

[39]  D. Benezra.  Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. , 1978, American journal of ophthalmology.

[40]  K Lund-Olesen,et al.  Oxygen tension in synovial fluids. , 1970, Arthritis and rheumatism.